Highland Therapeutics

Highland Therapeutics is a specialty pharmaceutical company focused on developing innovative treatments for Central Nervous System (CNS) disorders, particularly Attention Deficit Hyperactivity Disorder (ADHD). The company utilizes its proprietary DELEXIS drug delivery platform, which is designed to provide a delayed-release and extended-release profile, allowing for evening dosing to achieve therapeutic effect upon awakening the following morning. Its lead product, Jornay PM (methylphenidate), is FDA-approved and marketed through its subsidiary, Ironshore Pharmaceuticals. Highland continues to leverage its technology to optimize the delivery of existing medications to address unmet patient needs in the CNS space.